9,427
Views
4
CrossRef citations to date
0
Altmetric
Brief Report

Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice

ORCID Icon, , , , , , ORCID Icon & ORCID Icon show all
Article: e1405205 | Received 10 Oct 2017, Accepted 09 Nov 2017, Published online: 21 Dec 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Anne-Sophie Hamy, Lisa Derosa, Constance Valdelièvre, Satoru Yonekura, Paule Opolon, Maël Priour, Julien Guerin, Jean-Yves Pierga, Bernard Asselain, Diane De Croze, Alice Pinheiro, Marick Lae, Laure-Sophie Talagrand, Enora Laas, Lauren Darrigues, Beatriz Grandal, Elisabetta Marangoni, Elodie Montaudon, Guido Kroemer, Laurence Zitvogel & Fabien Reyal. (2020) Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer. OncoImmunology 9:1.
Read now
Kathleen M. Kokolus, Jeremy S. Haley, Emily J. Koubek, Raghavendra Gowda, Saketh S. Dinavahi, Arati Sharma, David F. Claxton, Klaus F. Helm, Joseph J. Drabick, Gavin P. Robertson, Jeffrey D. Neighbors, Raymond J. Hohl & Todd D. Schell. (2019) Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity. OncoImmunology 8:2.
Read now

Articles from other publishers (1)

Guanxi Qiao, Minhui Chen, Mark J. Bucsek, Elizabeth A. Repasky & Bonnie L. Hylander. (2018) Adrenergic Signaling: A Targetable Checkpoint Limiting Development of the Antitumor Immune Response. Frontiers in Immunology 9.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.